Linfoma anaplásico de células grandes: estudio clínico-patológico e inmunohistoquímica de 20 casos clasificados de acuerdo a la revisión de la Organización Mundial de la Salud de neoplasias linfoides de 2016

Sevilla-Lizcano, Diana Brisa; Ortíz-Hidalgo, Carlos

doi:10.24875/j.gamo.m17000075

Cited by 1 publication

(1 citation statement)

References 17 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extra-cutaneous spread occurs in 10% of cases and it is most likely to affect regional lymph nodes. Pc-ALCL should be distinguished from systemic ALCL with cutaneous involvement as a separate disease with distinct clinical and cytogenetic features, as well as different outcomes (see prior section) [ 94 , 99 ].…”

Section: Primary Cutaneous Alclmentioning

confidence: 99%

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas

Piña‐Oviedo

Ortíz-Hidalgo

Carballo-Zarate

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Anaplastic large cell lymphoma (ALCL) is a subtype of CD30+ large T-cell lymphoma (TCL) that comprises ~2% of all adult non-Hodgkin lymphomas. Based on the presence/absence of the rearrangement and expression of anaplastic lymphoma kinase (ALK), ALCL is divided into ALK+ and ALK-, and both differ clinically and prognostically. This review focuses on the historical points, clinical features, histopathology, differential diagnosis, and relevant cytogenetic and molecular alterations of ALK- ALCL and its subtypes: systemic, primary cutaneous (pc-ALCL), and breast implant-associated (BIA-ALCL). Recent studies have identified recurrent genetic alterations in this TCL. In systemic ALK- ALCL, rearrangements in DUSP22 and TP63 are detected in 30% and 8% of cases, respectively, while the remaining cases are negative for these rearrangements. A similar distribution of these rearrangements is seen in pc-ALCL, whereas none have been detected in BIA-ALCL. Additionally, systemic ALK- ALCL—apart from DUSP22-rearranged cases—harbors JAK1 and/or STAT3 mutations that result in the activation of the JAK/STAT signaling pathway. The JAK1/3 and STAT3 mutations have also been identified in BIA-ALCL but not in pc-ALCL. Although the pathogenesis of these alterations is not fully understood, most of them have prognostic value and open the door to the use of potential targeted therapies for this subtype of TCL.

show abstract

Section: Primary Cutaneous Alclmentioning

confidence: 99%